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Age-related diseaseThe insulin/IGF-1 signaling pathway is evolutionarily conserved and its function is mediated largely by FOXO
transcription factors. Reduced insulin/IGF-1 signaling leads to translocation of FOXO proteins from the cytoplasm
to the nucleus where they activate a set of genes that mediate oxidative stress, heat shock, and xenobiotic re-
sponses, innate immunity, metabolism, and autophagy. Disruptions in the insulin/IGF-1 signaling pathway affect
lifespan in many species. Over the past two decades, the function of these FOXO proteins in age-related diseases
has been extensively studied, in the model organism Caenorhabditis elegans as well as in humans. In this review
we investigate themechanisms bywhich FOXO proteins inﬂuence the development of age-related disease path-
ways in both species.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The process of aging and senescence is almost always accompanied
by the expression of disease and disorder. This creates amulti-stress en-
vironment and positions aging research in the ﬁeld of stress biology.a).
. This is an open access article underUnderstanding themechanisms underlying aging aswell as disease pro-
gression requires a fundamental insight into the gene regulatory re-
sponses to multi-stressors across species, including humans. But
invasive experimental genetic manipulations cannot be carried out in
humans for ethical as well as practical reasons and therefore more trac-
table species offer promising opportunities for studying the mecha-
nisms of aging and associated diseases. In this respect, the short-lived
nematode worm Caenorhabditis elegans (Nematoda, Rhabditidae) hasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.A schematic overview of the regulation of FOXO activity. Insulin-like signaling leads
to PI(3)K activation (Friedman and Johnson, 1988; Johnson, 1990), which induces Akt to
inhibit FOXO by phosphorylation (Henderson and Johnson, 2001). The human tumor sup-
pressor PTEN inhibits Akt activity, possibly by phosphorylation of PIP3 (not shown)
(Christensen et al., 2011). When cells are under oxidative stress, JNK activity increases
(Oh et al., 2005), while AMPK is activated by high AMP/ATP ratios (Apfeld et al., 2004;
Greer et al., 2007). Both kinases activate FOXO by phosphorylation (Apfeld et al., 2004;
Ohet al., 2005; Greer et al., 2007).WhenFOXO is active, it relocates to the nucleus and pro-
motes the expression of genes that promote longevity (Henderson and Johnson, 2001).
C. elegans homologs of mammalian proteins are shown in italics.
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Genetic investigations into the formation of dauer larvae have led to
the discovery of genes in the Insulin/IGF-1 signaling (IIS) pathway af-
fecting dauer stage formation that strongly affect lifespan. Among
these genes are daf-2, encoding an insulin-like receptor (Kenyon et al.,
1993; Kimura et al., 1997), daf-16, that encodes a FOXO-transcription
factor (Lin et al., 1997; Ogg et al., 1997), and age-1, the catalytic subunit
of class-I phosphatidylinositol 3-kinase (PI(3)K) (Friedman and
Johnson, 1988; Johnson, 1990). Daf-16 can be regarded as a master reg-
ulator. It regulates the transcription of a large number of genes involved
in abiotic and biotic stress resistance, and dauer formation, some of
which also affect longevity (Tullett, 2015). PI(3)K inhibits FOXO activity
through stimulation of Akt (AKT-1/2 in C. elegans) (Henderson and
Johnson, 2001).
Murakami and Johnson (1996)were among the ﬁrst to propose that
stress resistance and lifespan are together negatively regulated by a set
of gerontogenes, such as the daf-genes. DAF-16/FOXO plays a role in ox-
idative and heat stress and starvation (Henderson and Johnson, 2001)
and was found to be homologous to four FOXO transcription factors
found in humans, FOXO1, FOXO3a, FOXO4, and FOXO6 (Tzivion et al.,
2011). One of these four proteins, FOXO3a, has been directly associated
with prolonged lifespan in humans (Willcox et al., 2008; Anselmi et al.,
2009; Flachsbart et al., 2009; Soerensen et al., 2010). Apart from having
lifespan effects, FOXO transcription factors also inﬂuence age-related
diseases, such as cancer (Pinkston et al., 2006; Paik et al., 2007;
Pinkston-Gosse and Kenyon, 2007), osteoporosis (Iyer et al., 2013),
Alzheimer's disease (AD), and diabetes mellitus (DM) type II (Erol,
2007; Manolopoulos et al., 2010).
Herewe review theDAF-16/FOXOdiscoveriesmade in C. elegans and
discuss how they are instrumental in the analysis of complex age-
related disease pathways in humans.
2. FOXO transcription factors
2.1. Regulation involved in multi-stress response
FOXO transcription factors play an important role in the signal trans-
duction pathway associated with stress and aging phenotypes. This is
clearly illustrated by the fact that FOXO activity is strongly regulated
by cellular stress signals, especially oxidative stress (Fig. 1) which ulti-
mately modulates lifespan. Cellular stress signals lead to the induction
of speciﬁc stress-related kinases that activate FOXO by phosphorylation,
such as JUN kinase (JNK), that is part of the oxidative stress responseBox 1
C. elegans as a model organism for studying age-related diseases
Caenorhabditis elegans is a small saprophytic nematode of about
1 mm in length in the adult stage. It is a transparent self-
fertilizing hermaphrodite, producing both sperm and eggs.
C. elegansworms have a life cycle of about 3 days and an average
lifespan of 18 to 20 days when cultivated in vitro on Escherichia
coli at 20 °C. The postembryonic life cycle of C. elegans consists
of four larval stages, L1–L4, and a reproductive stage.Under unfa-
vorable conditions, the L2 stage can enter the dauer larval stage,
instead of developing into the regular L3 stage (Brenner, 1974).
Since the early 70s, many studies with C. elegans have led to new
discoveries in neuroscience, signal transduction, cell death, RNA
interference, environmental toxicology and biomedical science,
among others (Kenyon, 2011). Since the discovery of a genetic
pathway that appeared to greatly influence aging and stress resis-
tance in C. elegans (Tullet, 2015), it has also been used extensively
as a model organism in studies aiming to unravel lifespan
determination.(Oh et al., 2005), MST, that is involved in growth control (Lehtinen
et al., 2006), AMP activated protein kinase (AMPK in mammals, AAK-2
in C. elegans) responding to high AMP/ATP ratios (Apfeld et al., 2004;
Greer et al., 2007), and the p38MAP kinase pathway, that inﬂuences in-
nate immunity and stress response in C. elegans (Troemel et al., 2006).
When activated, DAF-16/FOXO relocates to the nucleus, upregulating
genes involved in stress response and cell survival and downregulating
developmental genes (Murphy et al., 2003). Another transcription fac-
tor, PQM-1, activates the developmental genes that are negatively regu-
lated byDAF-16/FOXO. Both transcription factorswork as antagonists to
one another tomaintain the balance between cell survival and develop-
ment (Tepper et al., 2013). SMK-1 (SMEK in mammals) is a nuclear co-
factor or co-regulator of the transcription of the target genes of FOXO
proteins under oxidative stress, in response to UV, and in innate immu-
nity (Wolff et al., 2006). By priming the stress response machinery of
the worm, increased lifespan can be achieved in which DAF-16/FOXO
plays a key role in combating stress and subsequent age-related disease
(Table 1).
2.2. DAF-16/FOXO also affects age-related disease
DAF-16/FOXO not only affects lifespan but is also involved in age-
related disease progression. For instance DAF-16/FOXO is linked to
germline tumorigenesis in C. elegans. Since there are no dividing somat-
ic cells in the C. elegans adult, only germline tumors occur in this organ-
ism. Mutations in the tumor suppressor gene known as gld-1 lead to
germline tumors that are lethal (Pinkston et al., 2006). In gld-1mutants,
germline cells re-enter the mitotic cell cycle early in the process of oo-
genesis, and start to proliferate rapidly. Eventually the cells will
Table 1
Age-related diseases inﬂuenced by DAF-16/FOXO and/or mammalian FOXO proteins.
Category Disease Pathology Inhibition Stimulation Evidence
Cancer Germline
tumorigenesis
(C. elegans)
Mutation gld-1 gene leads to uncontrolled proliferation of
germline cells.
DAF-16/FOXO upregulates nuclear pore proteins
which are required for p53 induced apoptosis of
germline cells.
Pinkston et al. (2006),
Pinkston-Gosse and
Kenyon (2007)
Tumorigenesis
(mammals)
Activation/mutation of proto-oncogenes and/or
inhibition/mutation of tumor suppressor genes leads to
uncontrolled proliferation of the affected cells. More
often than not, multiple genes need to be affected before
tumorigenesis occurs.
mTOR: FOXO activity inhibits the function of
mTORC1 by upregulation of TSC-1. This prevents
mTORC1 from stimulating increased glycolysis,
which leads to apoptosis resistance and tumor cell
survival.
Khatri et al. (2010),
Johnson et al. (2013)
HIF-1α: FOXO inhibits HIF-1α activity. The HIF-1α
transcription factor promotes VEGF-A activity,
which leads to blood vessel growth towards solid
tumors and can promote tumor growth as well as
metastasis.
Bakker et al. (2007),
Dansen and Burgering
(2008), Chiacchiera and
Simone (2009),
Chiacchiera et al. (2009)
ERβ: This receptor increases transcription of the
FOXO3a gene. FOXO3a activates PUMA, which
leads to p53-independent apoptosis in human
prostate cancer cells.
Yu and Zhang (2008), Dey
et al. (2014)
Metabolic
disease
Diabetes
mellitus II
(mammals)
Insulin resistance in peripheral tissues and decreased
insulin production by pancreatic beta cells lead to high
blood glucose levels and altered fat metabolism.
FOXO is activated by JNK under oxidative stress
conditions and in turn inhibits insulin-like signaling. This
can promote the development of insulin resistance which
further promotes degeneration of pancreatic beta cells
and thus the onset of DM II. It also increases production of
ROS, reactivating JNK.
Erol (2007),
Manolopoulos et al.
(2010)
Protein
aggregation
and
polyglutamine
Alzheimer's
disease
(mammals)
Formation of β-amyloid plaques and τ protein
phosphorylation in neurons causes neurodegeneration
and decreased cognitive function.
FOXO binds to β-catenin when activated by JNK,
inhibiting Wnt-signaling. This leads to increased
deposition of β-amyloid plaques and τ protein
phosphorylation, resulting in neurodegeneration. It also
causes an increase in ROS, reactivating JNK.
Erol (2007),
Manolopoulos et al.
(2010)
Duchenne
muscular
dystrophy
(C. elegans)
As a result of a loss-of-function mutation in the dys-1
gene in humans, muscle necrosis and degeneration
caused by dystrophin induced polyQ protein
aggregations occur.
In C. elegans, increased DAF-16/FOXO activity
protects from the polyQ protein aggregation
caused by mutation of the C. elegans ortholog of
the dys-1 gene.
Oh and Kim (2013)
Huntington's
disease
(mammals)
Expanding polyQ tracts in the huntingtin protein cause
protein aggregation resulting in neurodegeneration. This
leads to chorea, cognitive decline, and psychiatric
disorders.
Possibly depending on the stage of the disease,
FOXO3a activity has been shown to be capable of
stimulating the disease progression of HD.
Mojsilovic-Petrovic et al.
(2009), Jiang et al. (2011)
Possibly depending on the stage of the disease, FOXO3a
activity has been shown to be capable of protecting
against the disease progression of HD.
Davila et al. (2012), Davila
and Torres-Aleman
(2008)
Skeletal disease Osteoporosis
(mammals)
Decrease of bone formation during aging causes bones to
become more brittle.
Inhibition of Wnt-signaling by the binding of β-catenin by
FOXO leads to a decrease in bone formation by
osteoblasts, promoting osteoporosis.
Almeida et al. (2007),
Essers et al. (2005),
Manolagas and Almeida
(2007), Iyer et al. (2013)
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4 K. Hesp et al. / Experimental Gerontology 72 (2015) 1–7accumulate, leading to an early death (Pinkston et al., 2006). It was ob-
served that the germline cells and lifespan of daf-2 mutants, in which
DAF-16/FOXO is active, were not inﬂuenced bymutation of gld-1. In ad-
dition, it was found that DAF-16/FOXO, when activated, interacts with
p53 to induce germline apoptosis. In C. elegans, p53 only induces apo-
ptosis in germline cells in which DNA damage has occurred (genotoxic
stress), and not under normal circumstances. However, the C. elegans
p53 gene, cep-1, is not a DAF-16/FOXO target gene. Instead, it is postu-
lated that DAF-16/FOXO induces the same response in cells as if they
were under genotoxic stress, enabling p53 to stimulate apoptosis. Nu-
clear pore proteins, which are upregulated by DAF-16/FOXO, are neces-
sary for DAF-16/p53-dependent apoptosis. It has been suggested that
these proteins modify nuclear pores in such a way that a protein specif-
ically required for p53-dependent cell death can be transported through
them (Pinkston-Gosse and Kenyon, 2007). The induction of cell death
by DAF-16/FOXO is restricted to the germline tumor and does not affect
healthy tissue (Pinkston et al., 2006). In fact, normal germline cell death
is completely independent of DAF-16/FOXO aswell as of p53 (Pinkston-
Gosse and Kenyon, 2007). These ﬁndings underline that a strong corre-
lation exists between aging and the susceptibility to cancer develop-
ment. This suggests that tumorigenesis is inﬂuenced by genes that
regulate aging, such as daf-16 and its homologs (Pinkston et al., 2006).
2.2.1. Protein aggregation and polyglutamine
In addition to tumorigenesis, DAF-16/FOXO is a key player in the for-
mation of diseases due to protein aggregation and polyglutamine
(polyQ). In humans, neurodegenerative diseases, such as Huntington's
disease (HD) and AD, are associated with polyQ peptide chains in pro-
teins. These chains are formed because of expanding stretches of the
codon CAG in genes, encoding glutamine, leading to long stretches of
polyglutamines in the affected proteins. Generally, if the glutamine
chain lengths in the proteins expand beyond 35 to 40 residues, they be-
come cytotoxic in the nerve cells leading to cell death (Morley et al.,
2002; Khare et al., 2005; Morimoto, 2008). The onset of polyQ-
associated pathology correlates with the lifespan of C. elegans and this
is linked toDAF-16 (Morley et al., 2002). PolyQ-mediated protein aggre-
gation occurs rapidly in C. elegans in which the heat shock factor 1 gene,
hsf-1 is knocked down (Nollen et al., 2004). DAF-16/FOXO and heat
shock factor-1 (HSF-1) work partly together to promote longevity in
the absence of DAF-2 insulin-like signaling (Hsu et al., 2003). Together
DAF-16/FOXO and HSF-1 promote the expression of four small heat-
shock protein (sHSP) genes, hsp-16.1, hsp-16.49, hsp-12.6, and sip-1.
This suggests that DAF-16/FOXO is involved in heat-shock response
and that it also delays the formation of polyQ aggregations through
these four sHSP genes. The hypothesis that sHSPs inﬂuence protein ag-
gregation (Clark andMuchowski, 2000)was conﬁrmed by showing that
sHSPs bind to unfolded proteins and prevent them from aggregating
(Hsu et al., 2003; Fu, 2014). In the case of AD endoproteolysis of an
amyloid precursor protein (APP) leads to the formation of certain pep-
tides, Aβ1–42 in particular, that are prone to aggregation. Aβ1–42
aggregation is reduced in long-lived C. elegans mutants in which the
insulin/insulin growth factor-1-like signaling is knocked-down. DAF-
16/FOXO activity was involved in the reduction of SOD1 aggregate
neurotoxicity (Boccitto et al., 2012), also suggesting a protective role
of daf-16 in neurodegenerative diseases.
In addition to HD and AD, Duchenne muscular dystrophy is a fatal
muscle degenerative disease with no cure available at this time, which
is caused by loss-of-function mutations in the dys-1 gene. The dys-1
gene encodes dystrophin, which forms a complex with other proteins
known as dystrophin associated protein complex (DAPC) (Oh and
Kim, 2013). The result of a loss-of-function mutation in the dystrophin
gene in humans is muscle necrosis caused by proteotoxicity of dystro-
phin induced polyQ protein aggregations. Mutation of the C. elegans
ortholog of the dystrophin gene (also named dys-1) causes mildmuscle
degeneration as well as muscle contractility dysfunction. Reduced
insulin/IGF-1 signaling prevents protein aggregation and muscle celldeath in a manner dependent on DAF-16/FOXO (Oh and Kim, 2013).
Whether the mechanism by which this effect is mediated is the same
as in other polyQ-associated diseases still needs to be elucidated. A com-
bination of mutations in dys-1 with a daf-2 protects the dys-1 mutant
frommuscle cell death. Additionally, the lifespan of the daf-2;dys-1 dou-
ble mutants was extended to a level similar to that of the daf-2mutant
(Oh and Kim, 2013).
From these ﬁndings it can be concluded that degenerative diseases
and disorders of the neuronal system in C. elegans are strongly linked
to DAF-16/FOXO activity. This illustrates that research into lifespan
and aging associated DAF-16/FOXO provides important insights into
complex aging-related diseases of the nervous system.
3. Mammalian FOXO proteins
3.1. Cancer
While FOXO3A has been associated with long life in humans
(Willcox et al., 2008; Anselmi et al., 2009; Flachsbart et al., 2009;
Soerensen et al., 2010) it also, together with other FOXO transcription
factors, has been shown to play a role in tumor progression. Deletion
of FOXO1, FOXO3a, and FOXO4 in mice immediately resulted in tumor
growth (Paik et al., 2007). Notably, in most types of cancer, FOXO activ-
ity is inhibited by the overexpression of phosphoinositide 3-kinase
(PI(3)K) and protein kinase B (PKB or Akt) (Hu et al., 2004) which pro-
mote cytoplasmic retention and degradation of FOXO transcription fac-
tors. Although PI(3)K and Akt activities are very important, there are
also factors that regulate FOXO activity independently of these kinases.
3.1.1. FOXO proteins and mTOR under hypoxia
The mechanistic target of rapamycin (mTOR) is a key modulator of
aging and age-related disease and works antagonistically to FOXO pro-
teins. mTOR is incorporated in two cellular complexes, mTOR complex
1 (mTORC1) andmTORC2. The latter acts downstream of insulin signal-
ing components PI(3)K and Akt and is involved in the direct inhibition
of FOXO activity by insulin/IGF-1 signaling (Johnson et al., 2013).
mTORC1 is also activated by the PI(3)K/Akt kinase cascade and is a
key regulator of protein synthesis, lipidmetabolism, autophagy, inﬂam-
mation, and glycolysis. mTOR also activates hypoxia-inducible factor 1
alpha (HIF-1α), a transcription factor that negatively inﬂuences FOXO
activity (Johnson et al., 2013). FOXO proteins also upregulate the tuber-
ous sclerosis protein 1 (TSC-1) gene (tsc-1), which functions as a tumor
suppressor andwhich is an upstream inhibitor of mTORC1 (Khatri et al.,
2010; Johnson et al., 2013). However, the interaction between TSC-1,
mTORC1 and FOXO proteins is more intricate. Upon activation by Akt,
mTORC1 increases glycolysis in cells in which FOXO3a has been
knocked-down, by downregulating the expression of TSC-1. This
strongly suggests that FOXO3a prevents the effect of Akt-mediated
mTORC1-dependent glycolysis by controlling the transcription of tsc-1
(Khatri et al., 2010). Since increased glycolysis leads to apoptosis resis-
tance and thus tumor cell survival, this suggests another important
role for FOXO proteins in the prevention of tumorigenesis.
3.1.2. HIF-1α
FOXO proteins also suppress the development of new blood vessels
in tumor, and possibly even metastasis, by down-regulating the tran-
scription factor HIF-1α (Bakker et al., 2007). One of the main transcrip-
tional targets of this transcription factor is an attractant for endothelial
cells known as secreted vascular endothelial growth factor-A (VEGF-
A). This pathway stimulates growth of new blood vessels towards
solid tumors. HIF-1α is activated by mTORC1 (Khatri et al., 2010;
Johnson et al., 2013) at low levels of oxygen in cells as well as by high
levels of mitochondrial reactive oxygen species (ROS) (Simon, 2006;
Dansen and Burgering, 2008). FOXO activity upregulates the expression
of CITED2 that associates with the p300 transcriptional co-activator. In
doing so, it prevents the binding of p300 to HIF-1α and thus the
Fig. 2. Schematic overview of the inﬂuence of FOXO on development of DM and AD. Oxi-
dative stress activates JNK, which leads to increased FOXO activity. FOXO reduces both in-
sulin-like signaling (ILS) and Wnt signaling. Reduced ILS eventually leads to insulin
resistance, hyperglycemia and thus development of DMII (Erol, 2007; Manolopoulos
et al., 2010). The result of reduced Wnt signaling is the formation of β-amyloid plaques
as well as protein aggregation (not shown), that causes degeneration of neurons. This is
associated with the pathogenesis of AD (Manolopoulos et al., 2010). Development of
both diseases will eventually cause an increase in ROS, activating JNK and completing
the cycle (Erol, 2007; Manolopoulos et al., 2010).
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Burgering, 2008). It is possible that FOXO proteins also prevent HIF-1α
activity by upregulating the expression of MnSOD and other enzymes
that can scavenge ROS, since ROS can activate HIF-1α (Kops et al.,
2002; Simon, 2006). HIF-1α is also crucial for tumor cell survival be-
cause it upregulates the transcription of genes that mediate aerobic gly-
colysis. Tumor cells rely on constitutive aerobic glycolysis for their ATP
production (Chiacchiera and Simone, 2009; Chiacchiera et al., 2009). It
seems plausible that through thismechanismmTORC1 increases glycol-
ysis, since mTORC1 promotes HIF-1α activity. However, this has not yet
been conﬁrmed.
3.1.3. Apoptosis and the estrogen receptor β
Although FOXO transcription factors can prevent cells from entering
apoptosis (i.e. programmed cell-death) they are also capable of promot-
ing apoptosis (Dijkers et al., 2000; Tang et al., 2002; Dansen and
Burgering, 2008; Chapuis et al., 2010). They can promote the expression
of diverse apoptosis regulator genes such as Bcl-2-like protein (BIM)
(Dijkers et al., 2000), tumor necrosis factor ligand 6 (Fas ligand or
FasL) (Chapuis et al., 2010) and B-cell lymphoma 6 (BCL6) (Tang et al.,
2002). Which pathway FOXO transcription factors promote depends
on their binding to co-activators as well as other gene regulators
(Dansen and Burgering, 2008; van der Vos and Coffer, 2008).
Estrogen receptor β (ERβ) plays a crucial role in the induction of ap-
optosis in human prostate cancer cells. This effect is mediated by the
p53-upregulated modulator of apoptosis (PUMA) and is dependent on
FOXO3a, but not dependent on p53 (Yu and Zhang, 2008; Dey et al.,
2014). Interestingly, ERβ does not inﬂuence FOXO3a phosphorylation,
but it increases the transcription of the FOXO3a gene. This leads to
higher PUMA levels and consequently to apoptosis of the cancer cells
via caspase-9 (Dey et al., 2014).
Taken together, evidence is accumulating that mammalian FOXO
proteins are not only associatedwith long life but alsowith carcinogenic
phenotypes, very often related with hypoxia conditions.
3.2. Diabetesmellitus type II and Alzheimer's disease: FOXOunder oxidative
stress
FOXO transcription factors play a central role in the pathophysiolog-
ical processes of DM and AD. It seems that both diseases are affected by
the same positive feedback loop that starts with high levels of oxidative
stress. Additionally, the onset of one disease stimulates that of the other
and vice versa (Erol, 2007;Manolopoulos et al., 2010). In reaction to ox-
idative stress, JNK activates FOXO proteins by phosphorylation. FOXO
activity inhibits Akt and thereby insulin/IGF-1 signaling, which can
lead to a lower responsiveness of cells to insulin. Increased activity of
FOXO1 has been shown to directly decrease insulin sensitivity in liver,
pancreatic, and adipose cells (Nakae et al., 2002). This insulin resistance
leads to an increase in blood glucose levels and subsequently higher
levels of ROS, resulting in further activation of FOXO by JNK (Erol,
2007; Manolopoulos et al., 2010). Additionally, FOXO1 activity was
found to inhibit pancreatic β-cell differentiation by decreasing the ex-
pression of the pancreatic transcription factor pancreas/duodenum ho-
meobox gene-1 (Pdx1) (Kitamura et al., 2002). This would further
promote the development of DM II by reducing the production of
insulin. Constitutive JNK activity and FOXO activity are capable of
inhibiting Wnt signaling, leading to deposition of β-amyloid plaques, τ
protein phosphorylation, and subsequent neurodegeneration by apo-
ptosis. This process is strongly associated with AD pathogenesis
(Manolopoulos et al., 2010) and will also lead to the formation of
more ROS, completing the circle. These pathological processes in turn
lead to more oxidative stress and activate JNK again (Fig. 2) (Erol,
2007; Manolopoulos et al., 2010). It can be concluded that under oxida-
tive stress conditions, FOXO transcription factors play a central role in
complex diseases such as DM and AD.3.3. Huntington's disease
HD is an autosomal dominant disease which is caused by an
expanding polyQ tract in the huntingtin (HTT) protein. It is a neurode-
generative disordermarked by abnormal involuntarymovements (cho-
rea), cognitive decline, and psychiatric disorders (Huntington's Disease
Collaborative Research Group, 1993). In contrast to the protective role
of daf-16 in neurodegenerative diseases the functional effects of
FOXO3A on disease progression can be counteracting. On the one
hand FOXO3a has been shown to stimulate HD progression (Davila
and Torres-Aleman, 2008; Bahia et al., 2012; Davila et al., 2012)whereas
in other studies HD development was alleviated (Mojsilovic-Petrovic
et al., 2009; Jiang et al., 2011). It has been suggested that the inﬂuence
of FOXO3a activity differs between the early/mild stage of HD than in
the late/severe stage (Neri, 2012). More research is necessary to deter-
mine if FOXOs can be targeted for treatment of HD, and whether they
should be up- or downregulated to achieve this goal, possibly depend-
ing on the stage of the disease.3.4. Osteoporosis
During the aging process, the formation of new bone tissue declines
resulting in more brittle bones in a process known as osteoporosis. Os-
teoporosis has been linked to elevated activity of FOXO transcription
factors triggered by oxidative stress in combination with reduced pro-
duction of growth factors (Manolagas and Almeida, 2007; Iyer et al.,
2013). When cells are under oxidative stress, FOXO proteins physically
associate with β-catenin, which is then prevented from fulﬁlling its
role in Wnt signal transduction (Essers et al., 2005; Manolagas and
Almeida, 2007). Since Wnt signaling is involved the stimulation of
bone formation by osteoblasts, this leads to a decrease in bone forma-
tion (Almeida et al., 2007; Manolagas and Almeida, 2007; Iyer et al.,
2013). Bipotential progenitor cells (i.e. adipocyte or osteoblast) of
6 K. Hesp et al. / Experimental Gerontology 72 (2015) 1–7mice lacking FOXO1, FOXO3a, and FOXO4 activitymore often differenti-
ate into osteoblasts thanwild type controls. Furthermore, bone tissue in
these mutant mice remained denser with increasing age than con-
trols, and there was less adipose tissue formed in the bone marrow
(Iyer et al., 2013).
4. Perspectives
Research on components of the insulin-like signaling pathway and
daf-16 in C. elegans has facilitated the discovery of homologs of these pro-
teins in humans. These human homologs are not only key regulators of
aging, but also of age-related diseases. DAF-16/FOXO inﬂuences germline
tumorigenesis (Pinkston et al., 2006; Pinkston-Gosse and Kenyon, 2007)
and protein aggregation diseases (Clark and Muchowski, 2000; Morley
et al., 2002; Khare et al., 2005; Morimoto, 2008; Oh and Kim, 2013) in
C. eleganswhile human FOXO proteins are very important in protection
against cancer development (Dijkers et al., 2000; Hu et al., 2004;
Bakker et al., 2007; Paik et al., 2007; Dansen and Burgering, 2008; van
der Vos and Coffer, 2008; Yu and Zhang, 2008; Chiacchiera and Simone,
2009; Chiacchiera et al., 2009; Chapuis et al., 2010; Khatri et al., 2010;
Johnson et al., 2013; Dey et al., 2014). However, these proteins also
seem to promote the development of other age-related diseases such as
Alzheimer's, diabetes mellitus type II (Erol, 2007; Manolopoulos et al.,
2010) and osteoporosis (Almeida et al., 2007; Manolagas and Almeida,
2007; Iyer et al., 2013) and seem to have conﬂicting effects on the pro-
gression of Huntington's disease (Davila and Torres-Aleman, 2008;
Mojsilovic-Petrovic et al., 2009; Jiang et al., 2011; Bahia et al., 2012;
Davila et al., 2012; Neri, 2012). Because FOXO proteins are such key reg-
ulators, increasing or decreasing their activity for therapeutic purposes is
likely to have many unwanted side effects if not manipulated either very
speciﬁcally, or very locally. The fact that AD, DM type II, and osteoporosis
are less localized thanmost tumors complicates the use of FOXOproteins
as molecular targets in treatment of these diseases. Besides their poten-
tial for therapeutic application, further study of FOXO transcription fac-
tors and their functions could lead to a better understanding of how
increased human life expectancies and healthy aging could be achieved.
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